SELECT is an IRB-approved Observational Study aimed at evaluating patients’ experiences and/or perceptions and patient response for those who have been prescribed a CBD tincture or topical formulation by their clinician. Pain management, Anxiety, Sleep, Gastrointestinal, and Dermatologic symptoms will be evaluated by patient answers to validated measurement scales (e.g.; Brief Pain Inventory (BPI), Gastrointestinal Quality of Life Index (GIQLI-10), The Pittsburgh Sleep Quality Index (PSQI), The Hospital Anxiety and Depression Scale (HADS), and the Acne Quality of Life Questionnaire (Acne-Qol)) as well as additional survey questions regarding patient satisfaction, current medication usage, and resumption of their normal activities.
Become a Study Investigator
To learn more about our SELECT study, please call our dedicated Healthcare Provider HelpDesk at
(800) 616-9403.
Study Objective
The purpose of this minimal risk, observational study is to evaluate patients with mild, moderate, or chronic pain symptoms, sleep disorders, gastrointestinal disorders, anxiety disorder or dermatologic conditions (i.e. acne) and evaluate perceptions and efficacy of CBD treatment after the use of a CBD tincture or topical formulation.
Assessment Tools
Brief Pain Inventory (BPI), Gastrointestinal Quality of Life Index (GIQLI-10), The Pittsburgh Sleep Quality Index (PSQI), The Hospital Anxiety and Depression Scale (HADS), and the Acne Quality of Life Questionnaire (Acne-Qol)) as well as additional survey questions regarding patient satisfaction, current medication usage, and resumption of their normal activities.
Become a Study Investigator
To learn more about our SELECT study, please call our dedicated Healthcare Provider HelpDesk at
(800) 616-9403.